View Older Stories View More Recent Stories
-
Is Trump 2.0 good or bad for healthcare stocks?
-
Canaccord Genuity Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharma (ALNY) Announces U.S. FDA Acceptance of sNDA for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
TD Cowen Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Wolfe Research Downgrades Alnylam Pharmaceuticals (ALNY) to Underperform
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharma (ALNY) Tops Q3 EPS by 43c, Misses on Revenue; Offers FY24 Guidance
-
Canaccord Genuity Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $371 at TD Cowen
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharma (ALNY) Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
-
Canaccord Genuity Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
TD Cowen Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)
-
Piper Sandler Reiterates Overweight Rating on Alnylam Pharmaceuticals (ALNY)
-
Oppenheimer Reiterates Perform Rating on Alnylam Pharmaceuticals (ALNY)
-
Citi Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Goldman Sachs Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
BofA Securities Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharma (ALNY) Submits sNDA to FDA for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
-
Canaccord Genuity Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
TD Cowen Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Piper Sandler Reiterates Overweight Rating on Alnylam Pharmaceuticals (ALNY)
-
Goldman Sachs Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
BofA Securities Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
TD Cowen Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $307 at BofA Securities
-
Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Oppenheimer Reiterates Perform Rating on Alnylam Pharmaceuticals (ALNY)
-
Wolfe Research Reiterates Peerperform Rating on Alnylam Pharmaceuticals (ALNY)
-
TD Cowen Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Barclays Reiterates Overweight Rating on Alnylam Pharmaceuticals (ALNY)
-
Citi Reiterates Neutral Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharma (ALNY) Management Said There Was a Typo Error on Discussant Slide - Stat
-
BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY) following HELIOS-B readout
-
Stifel Reiterates Alnylam Pharmaceuticals (ALNY) at Buy following HELIOS-B readout, 'full HELIOS-B data look strong'
-
Ainylam Pharmaceuticals shares tumble following study results, BridgeBio Pharma rises
-
Alnylam Pharma (ALNY) Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran
-
BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)
-
RBC Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)
-
Goldman Sachs Upgrades Alnylam Pharmaceuticals (ALNY) to Buy
-
BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)
-
Eight defensive growth stocks to own right now
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $366 at Canaccord Genuity
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $300 at RBC Capital
-
Alnylam Pharma (ALNY) Tops Q2 EPS by $1.61
-
BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)

